These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38976226)

  • 1. Reply to: "Is the TAE score a promising prognostic predictor for unresectable hepatocellular carcinoma treated with TACE plus lenvatinib with PD‑1 inhibitors? Further validation should be performed".
    Zeng ZX; Wu JY; Zhuang SW; Yan ML
    Hepatol Int; 2024 Oct; 18(5):1589-1590. PubMed ID: 38976226
    [No Abstract]   [Full Text] [Related]  

  • 2. Is the TAE score a promising prognostic predictor for unresectable hepatocellular carcinoma treated with TACE plus lenvatinib with PD‑1 inhibitors? Further validation should be performed.
    Yang S; Liang H; Li X; Qian J; Ming Z
    Hepatol Int; 2024 Jun; 18(3):1058-1059. PubMed ID: 38717694
    [No Abstract]   [Full Text] [Related]  

  • 3. The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study.
    Ding Z; Fang G; Tang Y; Zeng Y
    Sci Rep; 2024 Jun; 14(1):14334. PubMed ID: 38906915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRAFITY score benefits hepatocellular carcinoma patients treated with transarterial chemoembolization and lenvatinib.
    Zhang L; Yang H; Ning S; Wu Z; Wang D; Liang H; Wang C; Chang X
    Cancer Med; 2024 Jun; 13(12):e7410. PubMed ID: 38923354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study.
    Tang Z; Bai T; Wei T; Wang X; Chen J; Ye J; Li S; Wei M; Li X; Lin Y; Tang J; Li L; Wu F
    BMC Cancer; 2024 Jun; 24(1):717. PubMed ID: 38862932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis.
    Liang Y; Gan L; Zeng D; Lin L; Xiong Z; Liao F; Wang A
    Clin Transl Oncol; 2024 Oct; 26(10):2652-2664. PubMed ID: 38671328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
    Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
    Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
    [No Abstract]   [Full Text] [Related]  

  • 8. Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: A real-world observational study.
    Li X; Wang X; Bai T; Chen J; Lu S; Wei T; Tang Z; Zhao G; Lu H; Li L; Wu F
    Dig Liver Dis; 2024 Jun; 56(6):1078-1086. PubMed ID: 38114383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors.
    Zeng ZX; Wu JY; Wu JY; Li YN; Fu YK; Zhang ZB; Liu DY; Li H; Ou XY; Zhuang SW; Yan ML
    Hepatol Int; 2024 Apr; 18(2):651-660. PubMed ID: 38040945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma.
    Sheng Y; Wang Q; Liu H; Wang Q; Chen W; Xing W
    Br J Radiol; 2024 Feb; 97(1155):668-679. PubMed ID: 38303541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination Therapy Consisting of Transarterial Chemoembolization, Lenvatinib, and Programmed Cell Death Protein 1 Blockade for Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombus: A Case Series Study and Literature Review.
    Fu YK; Li YN; Liu DY; Zeng ZX; Wu JY; Wu JY; Wang JX; Li H; Ou XY; Yan ML
    Oncol Res Treat; 2024; 47(10):465-473. PubMed ID: 39111295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiency and Stability of Transarterial Chemoembolization Combined With or Without Lenvatinib for Unresectable Hepatocellular Carcinoma.
    Zong Z; Tang R; Li M; Xiong X; Li D; Fan J; Ye W; Xue C
    Turk J Gastroenterol; 2024 Mar; 35(3):212-222. PubMed ID: 39128062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
    Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
    Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial chemoembolization combined with sintilimab and lenvatinib for the treatment of unresectable hepatocellular carcinoma: a retrospective study.
    Shen C; Jiang W; Chen R; Li L; Wu Y; Tan L; Chen Y; Zhang W; Wang Z
    J Cancer Res Clin Oncol; 2024 Sep; 150(9):427. PubMed ID: 39302490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial Chemoembolization Combined with Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Pei X; Zhao J; Wang Z
    Oncology; 2024; 102(8):688-702. PubMed ID: 38190815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study.
    Chen S; Shuangyan T; Shi F; Cai H; Wu Z; Wang L; Ma P; Zhou Y; Mai Q; Wang F; Lai J; Chen X; Chen H; Guo W
    Front Immunol; 2024; 15():1430571. PubMed ID: 39131156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study.
    Chen Y; Zhang J; Hu W; Li X; Sun K; Shen Y; Zhang M; Wu J; Gao S; Yu J; Que R; Zhang Y; Yang F; Xia W; Zhang A; Tang X; Bai X; Liang T
    Signal Transduct Target Ther; 2024 Oct; 9(1):280. PubMed ID: 39384742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis.
    Chen Y; Jia L; Li Y; Cui W; Wang J; Zhang C; Bian C; Luo T
    Front Immunol; 2024; 15():1466113. PubMed ID: 39281676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors superior to TACE plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: the debate continues.
    Yang S; Liang H; Li X; Qian J; Ming Z
    Hepatol Int; 2024 Aug; 18(4):1336-1337. PubMed ID: 38329702
    [No Abstract]   [Full Text] [Related]  

  • 20. Transarterial Chemoembolization Combined with Lenvatinib Plus Sequential Microwave Ablation for Large Hepatocellular Carcinoma Beyond Up-to-Seven Criteria: A Retrospective Cohort Study.
    Tang L; Hou Y; Huang Z; Huang J
    Acad Radiol; 2024 Jul; 31(7):2795-2806. PubMed ID: 38290885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.